The need for non-invasive tools for diagnosis and follow up led to the identification of protein biomarkers in the urine, such as Nuclear Matrix Protein 22 (NMP-22) and Bladder Tumor Antigen, which are currently FDA approved but are yet to be widely adopted by the urologic community [10]. This evidence concerns the gene NUMA1 and neoplasm.